Similarly, highly significant differences were found in the almotriptan-treated versus the placebo group in 2-h pain-free (37.0% vs 23.9%, p = 0.010), 2-h pain relief (72.3% vs 48.4%, p < 0.001) and SPF (24.7% vs 16.1%, p = 0.040) rates.
The difference in term of treatment-emergent AEs and treatment-related AEs was favorable to almotriptan with an almost significant difference (p = 0.06) in the treatment-emergent AEs (15.2% almotriptan, 19.4% sumatriptan) and with high level of significance (p = 0.001) in the treatment-related AEs (9.1% almotriptan, 15.5% sumatriptan) with respect to sumatriptan, including the incidence of chest pain (0.3 vs 2.2%, p = 0.004).
The recurrence rate within 24 h of a moderate or severe headache was 27.4% after treatment with almotriptan and 24.0% after treatment with sumatriptan, a difference that did not reach statistical significance.